What is the appropriate dosage of methotrexate for an adult with rheumatoid arthritis?

Methotrexate Dosing for Rheumatoid Arthritis

For adults with rheumatoid arthritis, start methotrexate at 7.5 mg orally once weekly, with rapid titration to at least 15 mg weekly within 4-6 weeks, and consider escalation up to 20-25 mg weekly based on response and tolerability. 1, 2

Starting Dose and Route

• Initial dosing options include either a single oral dose of 7.5 mg once weekly OR divided oral doses of 2.5 mg at 12-hour intervals for 3 doses given as a course once weekly 2
• Oral administration is preferred initially over subcutaneous methotrexate due to ease of administration and similar bioavailability at typical starting doses, despite moderate evidence suggesting superior efficacy of subcutaneous injections 1
• Starting doses should not be less than 10 mg/week according to expert consensus, with preference for higher initial doses to optimize early response 3, 4, 5

Dose Escalation Strategy

• Titrate to at least 15 mg weekly within 4-6 weeks of initiation, as this approach is conditionally recommended to balance efficacy against toxicity risk 1
• Rapid dose escalation is appropriate if inadequate response occurs, with increments of 2.5-5 mg every 4-6 weeks up to 20-25 mg/week 3, 4
• Maximum effective dose is typically 20-25 mg/week, with doses greater than 20 mg/week associated with significantly increased risk of serious toxic reactions, especially bone marrow suppression 2
• Doses should not ordinarily exceed 30 mg/week per FDA labeling 2

When to Switch to Subcutaneous Administration

Switch from oral to subcutaneous methotrexate in the following situations 1:

• Inadequate response to oral methotrexate at optimized doses
• Gastrointestinal side effects or intolerance to oral administration
• Poor compliance with oral therapy
• Doses required are >20 mg/week (better absorption with parenteral route at higher doses) 2
• Patient preference or obesity

Subcutaneous methotrexate is conditionally recommended over adding/switching to alternative DMARDs for patients taking oral methotrexate who are not at target, consistent with maximizing methotrexate use before escalating therapy 1

Alternative Strategies for Oral Intolerance

Before switching to subcutaneous or alternative DMARDs, consider 1:

• Split dosing of oral methotrexate over 24 hours
• Increased folic/folinic acid supplementation (minimum 5 mg folic acid once weekly, at a distance from methotrexate dose) 5
• These strategies are preferred initially due to methotrexate's efficacy, long-term safety, and low cost

Monitoring Requirements

Baseline assessment must include 2, 5:

• Complete blood count
• Serum creatinine with creatinine clearance calculation
• Liver function tests (transaminases)
• Chest radiograph
• Hepatitis B and C serologies (recommended)
• Serum albumin (recommended)

Ongoing monitoring schedule 5:

• Full blood count, liver enzymes, and creatinine at least monthly for first 3 months
• Then every 4-12 weeks thereafter during stable therapy
• More frequent monitoring (every 1-1.5 months) until disease stability achieved 3

Expected Response Timeline

• Therapeutic response typically begins within 3-6 weeks of initiating treatment 2
• Continued improvement may occur for another 12 weeks or more after initial response 2
• Maximal myelosuppression usually occurs in 7-10 days after dosing 2

Important Caveats

Oral methotrexate at doses of 15-25 mg/week is non-inferior to parenteral administration regarding efficacy and safety, supporting initial therapy with oral methotrexate before considering route change 6. However, parenteral administration shows advantages in bioavailability (AUC) and may be preferred for patients requiring higher doses or experiencing gastrointestinal side effects 6.

Contraception is mandatory during methotrexate therapy due to teratogenic effects 2.